Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphoma
NCT02809573Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Aug 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tucidinostat in peripheral T-cell lymphoma (PTCL), sponsored by Akeso, Inc. Primary endpoint: Dose-limiting toxicity. Started Aug 2016; status: completed.
02
Drugs
tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02809573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02809573.